BRF
IMMU

B. Riley Financial’s Immunomedics Inc IMMU Stock Holding History

B. Riley Financial’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,384
Closed -$425K – 217
2018
Q3 		$425K Buy
20,384
+5,480
+37% +$130K 0.12% 126
2018
Q2 		$353K Buy
+14,904
New +$300K 0.09% 211

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

B. Riley Financial's IMMU Position: Q4 2018 in Review

B. Riley Financial sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 20,384 shares — an estimated $425K sold.

B. Riley Financial first reported a position in IMMU in Q2 2018 and held it in 2 quarters. The position peaked at $425K in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • B. Riley Financial reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • B. Riley Financial sold 20,384 Immunomedics Inc shares in Q4 2018, an estimated $425K.
  • B. Riley Financial first reported a position in Immunomedics Inc in Q2 2018 and held it in 2 quarters.
  • B. Riley Financial's Immunomedics Inc position peaked at $425K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on B. Riley Financial's 13F filing for Q4 2018, filed 7 Feb 2019.